Why the study?
Does dose-dependent ACE inhibition or AT1-receptor blockade improve cardiac function and normalize ANF and SR Ca(2+)-ATPase gene expression in renal hypertensive rats?
Does dose-dependent ACE inhibition or AT1-receptor blockade improve cardiac function and normalize ANF and SR Ca(2+)-ATPase gene expression in renal hypertensive rats?
High-dose ACE inhibition or AT1-receptor blockade is required to normalize systolic wall stress and restore normal SR Ca(2+)-ATPase and ANF gene expression in renal hypertensive rats.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in renal hypertensive rats; leaves open translation to human LV remodeling or dosing.
BACKGROUND: Cardiac hypertrophy is associated with altered Ca2+ handling and may predispose to the development of LV dysfunction and cardiac failure. At the cellular level, the re-expression of ANF represents a well-established marker of myocyte hypertrophy while the decreased expression of the sarcoplasmatic reticulum (SR) Ca(2+)-ATPase is thought o play a crucial role in the alterations of Ca2+ handling and LV function. We assessed the dose-dependent effect of chronic ACE inhibition or AT1 receptor blockade on cardiac function in relation to the cardiac expression of the SR Ca(2+)-ATPase and ANF. METHODS AND RESULTS: Renal hypertensive rats (2K-1C) were treated for 12 weeks with three different doses of the ACE inhibitor benazepril, the AT1-receptor antagonist valsartan (each drug 0.3, 3, and 10 mg/kg per day i.p.) or placebo. LV dimensions, hypertrophy and wall stress were determined in vivo by magnetic resonance imaging and the gene expressions of ANF and SR Ca(2+)-ATPase were quantified by Northern blot. Low doses of both drugs did not affect blood pressure, hypertrophy, systolic wall stress and the ANF and SR Ca(2+)-ATPase gene expression. High doses of each drug reduced systolic blood pressure, wall stress, and LV hypertrophy to a similar extent and to values comparable to normotensive, age-matched rats. In addition, high dose treatment reduced LV end-systolic and end-diastolic volume as compared to untreated 2K-1C animals and normalized the mRNA levels of both ANF and SR Ca(2+)-ATPase (as compared to normotensive animals). CONCLUSIONS: We conclude that in this model, high doses of ACE inhibition and AT1-receptor blockade are necessary to normalize systolic blood pressure, LV hypertrophy and systolic LV wall stress which, in turn, is associated with restoration of a normal cardiac phenotype with respect to SR Ca(2+)-ATPase and ANF and normalization of cardiac function.
No takes yet. Share an insight, caveat, or question.
Zierhut et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: